Corporate Banner
Satellite Banner
Technology Networks Header
Sunday, November 23, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Plate Reader versus High Content RNAi Screens. Who's Right?
  Videos

Return

Plate Reader versus High Content RNAi Screens. Who's Right?
Sheffield University

There are few research areas that have expanded as quickly and spectacularly as the field of RNA interference (RNAi). RNAi based research is now maturing into a multi-billion pound industry. The notion that we can systematically switch off every gene in the genome and screen for important biological processes has become both practical and routine. Marrying this technology with High Content Microscopy we are capable of asking important phenotypic questions in a systematic way. The Sheffield RNAi Screening Facility was born from the fundamentals of the initially highly successful Drosophila melanogaster screening platform and now we operate both the Fruit Fly and Human systems. Due to the ability to compare two screens from different organisms for the first time, results will be presented from a high content siRNA screen in a Human cell line, comparing results to previously intensive screens from 3 genome-wide Drosophila screens completed using a plate reader platform. We will present the benefits and difficulties of both cellular platforms. While presenting the results, we will discuss issues such as the complexities of the type of screening approach adopted.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Direct Drug Screening Of Biopsies Could Overcome Resistance
Combining genetic with pharmacologic screening of tumors may enable truly individualized treatment regimens.
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Next-Gen Melanoma Drug Excels in Lab Tests
Anti-cancer activity was reported in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733.
Blood Test Could Reduce Antibiotic Use
A new blood biomarker test that indicates whether bacteria is the cause of a patient’s lung infection is now being studied at UPMC Presbyterian.
New Targets and Test to Develop Treatments for Memory Disorders
The study focuses on kinesin, a molecular motor protein that plays a role in the transport of other proteins throughout a cell.
Drugging the Undruggable
Discovery opens up possibility of slowing cancer spread.
Classification of Gene Mutations in Neuroblastoma
Penn Medicine and CHOP experts define riskier mutations in neuroblastoma, setting stage for clinical trial.
Microscopic “Walkers” Find Their Way Across Cell Surfaces
Technology could provide a way to deliver probes or drugs to cell structures without outside guidance.
Study Investigates Inherent Contamination in Deep Well Microplates
Study gives data on microplates from numerous manufacturers based in Europe, USA and China.
Culture System Replicates Course Of Alzheimer’s Disease
Three-dimensional system should significantly reduce time and costs of drug development.
Scroll Up
Scroll Down
Skyscraper Banner
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv